Product: Soliris® eculizumab

Disease: PNH

Indication: Treatment of paroxysmal nocturnal hemoglobinuria.

Product: Ferriprox ® deferiprone

Disease: Thalassaemia

Indication: Treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.

Product: Novoseven® eptacog alfa (activated)

Disease: Haemophillia & FVII deficiency

Indication: Indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 Bethesda Units (BU) • in patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration • in patients with acquired haemophilia • in patients with congenital FVII deficiency • in patients with Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA, and with past or present refractoriness to platelet transfusions.

Product: Human Immune Globulin (Rho(D) IGIV

Disease: Immune Thrombocytopenic Purpura (ITP)

Indication: Treatment of Immune Thrombocytopenic Purpura (ITP) Suppression of Rh Isoimmunization

Product: Recombinant coagulation factor VIII

Disease: Hemophillia

Indication: Antihemophilic Factor (Recombinant) indicated for:• Control and prevention of bleeding episodes in adults and children (0-16years) with hemophilia A.• Peri-operative management in adults and children with hemophilia A.• Routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no pre-existing joint Damage.

Product: Human normal immunoglobulin Solution for infusion (10%)

Disease: Immunoglobulin

Indication: Replacement therapy in • Primary immunodeficiency syndromes such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia - common variable immunodeficiency - severe combined immunodeficiency - Wiskott-Aldrich syndrome • Myeloma or chronic lymphocyticleukaemia with severe secondary hypogammaglobulinaemia and recurrent infections • Children with congenital AIDS and recurrent infections Immunomodulation • Immune thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding or prior to surgical interventions to correct the platelet count• Guillain-Barré syndrome • Kawasaki disease  Allogeneic bone marrow transplantation

Product: human plasma-derived von Willebrand Factor-ristocetin co-factor activity (VWF:RCo) and human coagulation factor VIII activity (FVIII:C)

Disease: Von Willebrand Disease & Haemophilia A

Indication: Von Willebrand Disease (VWD) Prophylaxis and treatment of haemorrhage or surgical bleeding, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Haemophilia A Prophylaxis and treatment of bleeding. Haemate P may be used in the management of acquired FVIII deficiency and for treatment of patients with antibodies against factor VIII.